GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has...
NYSE: NVO
Novo Nordisk’s Wegovy Granted FDA Approval for Metabolic-Associated Steatohepatitis
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced on August 15, 2025, that its...
Novo Nordisk Reports Strong H1 2025 Financial Results Driven by Semaglutide Sales
Danish biopharmaceutical giant Novo Nordisk A/S (NYSE: NVO) announced its financial results for the first...
Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered
Shares of Denmark-based biopharma giant Novo Nordisk A/S (NYSE: NVO) dipped over 20% during trading...
Novo Nordisk’s Ozempic Approved for Kidney Protection in China, Pioneering Glycemic and Renal Control
The National Medical Products Administration has granted approval to Novo Nordisk’s (NYSE: NVO) once-weekly semaglutide...
Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)...
Yifan Pharma Wins NMPA Approval for Norditropin Biosimilar Trial
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that it has received clinical trial approval...
Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...
Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...
Novo Nordisk Advances Amycretin for Weight Management in Phase III Trials
Denmark-based pharmaceutical major Novo Nordisk (NYSE: NVO) announced plans to advance both subcutaneous and oral...
NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery
US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo...
Novo Nordisk’s Wegovy Demonstrates Early Cardioprotective Effects in SELECT Trial
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced groundbreaking secondary analysis results from...
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges
Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...
Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...
Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...
Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...
Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...
Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone
Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...